Literature DB >> 3543027

Quantitation of protein kinase C by immunoblot--expression in different cell lines and response to phorbol esters.

S Stabel, A Rodriguez-Pena, S Young, E Rozengurt, P J Parker.   

Abstract

Antisera have been raised against human protein kinase C and also against a synthetic peptide based on the sequence of the bovine brain enzyme (LLNQEE-GEYYNVPIPE). These antibodies react with protein kinase C from a number of species (human, murine, rat, rabbit, bovine), indicating substantial conservation of epitopes. These antisera have been used to quantitate directly protein kinase C by immunoblot analysis. We show here that there is a strict correlation between the levels of immunoreactive polypeptide and extractable calcium- and phospholipid-dependent kinase activity for various cell lines. Treatment of murine, rat, and human cells with phorbol dibutyrate was found to deplete levels of immunoreactive protein kinase C severely. A detailed study of the time course of this depletion in Swiss 3T3 cells shows that it follows precisely the loss of extractable activity. On exposure to 400 nM phorbol 12,13-dibutyrate protein kinase C was essentially undetectable by 40 hours; the half-life of this down-regulation was 6.7 hours. This data thus demonstrate that the loss of immunoreactive protein kinase C and of extractable calcium- and phospholipid-dependent kinase activity precisely parallels the phorbol ester induced down-regulation of binding and responsiveness in Swiss 3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3543027     DOI: 10.1002/jcp.1041300116

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  22 in total

1.  Studies on the phosphorylation of protein kinase C-alpha.

Authors:  C Pears; S Stabel; S Cazaubon; P J Parker
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

2.  Protein kinase C group B members PKC-delta, -epsilon, -zeta and PKC-L(eta). Comparison of properties of recombinant proteins in vitro and in vivo.

Authors:  M Liyanage; D Frith; E Livneh; S Stabel
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

3.  Signal-transduction-pathway-specific desensitization of expression of orphan nuclear receptor TIS1.

Authors:  R W Lim; W L Yang; H Yu
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

4.  Endothelin stimulates DNA synthesis in Swiss 3T3 cells. Synergy with polypeptide growth factors.

Authors:  K D Brown; C J Littlewood
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

5.  The phosphorylation of protein kinase C as a potential measure of activation.

Authors:  F E Mitchell; R M Marais; P J Parker
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

6.  Identification of the proteolytically activated form of protein kinase C in stimulated human neutrophils.

Authors:  S Pontremoli; M Michetti; E Melloni; B Sparatore; F Salamino; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

7.  Involvement of protein kinase C in growth regulation of human meningioma cells.

Authors:  T Todo; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Whole-cell recording of neuroblastoma x glioma cells during downregulation of a major substrate, 80K/MARCKS, of protein kinase C.

Authors:  M M Civan; J Robbins; S Broad; E Rozengurt; D A Brown
Journal:  J Membr Biol       Date:  1993-04       Impact factor: 1.843

9.  Overexpression of the alpha-type protein kinase (PK) C in LLC-PK1 cells does not lead to a proportional increase in the induction of two 12-O-tetradecanoylphorbol-13-acetate-inducible genes.

Authors:  M Wartmann; D A Jans; P J Parker; Y Nagamine; B A Hemmings; S Jaken; U Eppenberger; D Fabbro
Journal:  Cell Regul       Date:  1991-06

Review 10.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.